NCT00518570 - Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

October 31, 2006

Conditions

Premenstrual Dysphoric Disorder

Interventions

DRUG

Levetiracetam

Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.

Trial Locations (1)

01201

Berkshire Medical Center, Clinical Trials Program, Department of Psychiatry, Pittsfield